SCHEMBL3015459

SCHEMBL3015459

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.52
SMN1; SMN2 Q16637 5/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
NPSR1 Q6W5P4 1/20 0.41
MAPK1 P28482 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
USP2 O75604 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TP53 P04637 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022225 0.89 AR (0.53) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3014549 0.89 AR (0.53) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3015049 0.88 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AMAPTNPC1NPSR1
SCHEMBL3017157 0.88 AR (0.60) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3012500 0.87 SMN1; SMN2 (0.51) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3016907 0.87 AR (0.57) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3019169 0.86 AR (0.54) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3018834 0.86 AR (0.56) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3009932 0.86 AR (0.50) ARSMN1; SMN2RAB9AMAPTNPC1
SCHEMBL3021277 0.86 AR (0.60) ARSMN1; SMN2RAB9AMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.